Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine

The relationship between acetylcholinesterase (AChE) activity in the CSF and brain of patients with Alzheimer's disease (AD) was investigated in 18 mild AD patients following galantamine treatment. The first 3 months of the study had a randomized double-blind placebo-controlled design, during which 12 patients received galantamine (16-24 mg/day) and six patients placebo. This was followed by 9 months galantamine treatment in all patients. Activities and protein levels of both the "read-through" AChE (AChE-R) and the synaptic (AChE-S) variants in CSF were assessed in parallel together with the regional brain AChE activity by (11)C-PMP and PET. The AChE-S inhibition was 30-36% in CSF, which correlated well with the in vivo AChE inhibition in the brain. No significant AChE inhibition was observed in the placebo group. The increased level of the AChE-R protein was 16% higher than that of AChE-S. Both the AChE inhibition and the increased level of AChE-R protein positively correlated with the patient's performance in cognitive tests associated with visuospatial ability and attention. In conclusion, AChE levels in CSF closely mirror in vivo brain AChE levels prior to and after treatment with the cholinesterase inhibitors. A positive cognitive response seems to dependent on the AChE inhibition level, which is balanced by an increased protein level of the AChE-R variant in the patients.

[1]  David E. Kuhl,et al.  Kinetic Modeling of N-[11C]Methylpiperidin-4-yl Propionate: Alternatives for Analysis of an Irreversible Positron Emission Tomography Tracer for Measurement of Acetylcholinesterase Activity in Human Brain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  A. Luria.  Higher Cortical Functions in Man , 1980, Springer US.

[3]  L. Minthon,et al.  Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer’s disease following chronic donepezil treatment , 2006, Journal of Neural Transmission.

[4]  Christopher J Czura,et al.  Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Legay,et al.  The polymorphism of acetylcholinesterase: post-translational processing, quaternary associations and localization. , 1999, Chemico-biological interactions.

[6]  I. McKeith,et al.  Regulation of attention and response to therapy in dementia by butyrylcholinesterase. , 2003, Pharmacogenetics.

[7]  J. Massoulie,et al.  The C-terminal peptides of acetylcholinesterase: cellular trafficking, oligomerization and functional anchoring. , 2005, Chemico-biological interactions.

[8]  J. Birks,et al.  Cholinesterase inhibitors for Alzheimer's disease. , 2006 .

[9]  N. Bohnen,et al.  Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  K. Tracey,et al.  Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation , 2005, The Journal of experimental medicine.

[11]  T. Darreh-Shori.  Molecular changes of acetylcholinesterase and butyrylcholinesterase in Alzheimer patients during the natural couse of the disease and treatment with cholinesterase inhibitors : Insight into neurochemical mechanisms affecting the progression of the disease , 2006 .

[12]  E. Mann,et al.  A novel peptide modulates α7 nicotinic receptor responses: implications for a possible trophic‐toxic mechanism within the brain , 2004, Journal of neurochemistry.

[13]  H. Soreq,et al.  Virtues and woes of AChE alternative splicing in stress-related neuropathologies , 2006, Trends in Neurosciences.

[14]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[15]  S. Brimijoin,et al.  Butyrylcholinesterase in Human Brain and Acetylcholinesterase in Human Plasma: Trace Enzymes Measured by Two‐Site Immunoassay , 1988, Journal of neurochemistry.

[16]  H. Soreq,et al.  Hydrolytic and Nonenzymatic Functions of Acetylcholinesterase Comodulate Hemopoietic Stress Responses1 , 2006, The Journal of Immunology.

[17]  E. Krejci,et al.  PRiMA The Membrane Anchor of Acetylcholinesterase in the Brain , 2002, Neuron.

[18]  J. Patrick,et al.  Excess "read-through" acetylcholinesterase attenuates but the "synaptic" variant intensifies neurodeterioration correlates. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. No̸rgaard-Pedersen,et al.  Subunit Association and Glycosylation of Acetylcholinesterase from Monkey Brain , 1993, Journal of neurochemistry.

[20]  S. Greenfield.  A peptide derived from acetylcholinesterase is a pivotal signalling molecule in neurodegeneration. , 2005, Chemico-biological interactions.

[21]  H. Geerts,et al.  Nicotinic cholinergic modulation: galantamine as a prototype. , 2006, CNS drug reviews.

[22]  S. Tyrrell.  NO CHILDHOOD , 1975, The Lancet.

[23]  L. Bäckman,et al.  Episodic memory functioning in a community-based sample of old adults with major depression: utilization of cognitive support. , 1994, Journal of abnormal psychology.

[24]  M. Shapira,et al.  ARP, A Peptide Derived from the Stress-Associated Acetylcholinesterase Variant, Has Hematopoietic Growth Promoting Activities , 2001, Molecular medicine.

[25]  J L Sussman,et al.  Electrotactins: a class of adhesion proteins with conserved electrostatic and structural motifs. , 1998, Protein engineering.

[26]  C. Geula,et al.  Immunocytochemical demonstration of axonal and perikaryal acetylcholinesterase in human cerebral cortex , 1991, Brain Research.

[27]  J. Yesavage,et al.  Brain structural and cognitive correlates of clock drawing performance in Alzheimer's disease , 1999, Journal of the International Neuropsychological Society.

[28]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[29]  E. Giacobini,et al.  Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit , 2002, Journal of Neural Transmission.

[30]  E. Giacobini,et al.  The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex , 1996, Neuropharmacology.

[31]  H. Soreq,et al.  Interaction of “readthrough” acetylcholinesterase with RACK1 and PKCβII correlates with intensified fear-induced conflict behavior , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Mori,et al.  What Constitutes Clinical Evidence for Neuroprotection in Alzheimer Disease: Support for the Cholinesterase Inhibitors? , 2006, Alzheimer disease and associated disorders.

[33]  W. Markesbery,et al.  Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  H. Soreq,et al.  Functional manipulations of acetylcholinesterase splice variants highlight alternative splicing contributions to murine neocortical development. , 2005, Cerebral cortex.

[35]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[36]  A. Nordberg,et al.  Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months , 2002, Neurology.

[37]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[38]  A. Maelicke.  Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer’s Disease , 2000, Dementia and Geriatric Cognitive Disorders.

[39]  M. Shapira,et al.  A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. , 2000, Human molecular genetics.

[40]  T. Pollmächer,et al.  Endotoxin-induced changes in human working and declarative memory associate with cleavage of plasma “readthrough” acetylcholinesterase , 2007, Journal of Molecular Neuroscience.

[41]  A. Engel,et al.  Acetylcholinesterase of human erythrocytes and neuromuscular junctions: homologies revealed by monoclonal antibodies. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Farlow,et al.  A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease , 2000, European Neurology.

[43]  S. Brimijoin,et al.  Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE ε4 allele, in relation to cognitive function and cerebral glucose metabolism , 2006, Neurobiology of Disease.

[44]  I. Chubb,et al.  Is acetylcholinesterase secreted from central neurons into the cerebrospinal fluid? , 1976, Neuroscience.

[45]  D. Kaufer,et al.  Acute stress facilitates long-lasting changes in cholinergic gene expression , 1998, Nature.

[46]  O. Lockridge,et al.  Comparison of atypical and usual human serum cholinesterase. Purification, number of active sites, substrate affinity, and turnover number. , 1978, The Journal of biological chemistry.

[47]  A. Wall,et al.  PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD , 2008, Neurobiology of Aging.

[48]  Kaj Blennow,et al.  Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease , 2001, Neuroscience Letters.

[49]  A. Nordberg,et al.  Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients , 2004, European journal of neurology.

[50]  J. Cummings,et al.  Frontal-subcortical circuits and human behavior. , 1993, Journal of psychosomatic research.

[51]  E. Giacobini.  Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[52]  K. Tracey,et al.  It takes nerve to dampen inflammation , 2005, Nature Immunology.

[53]  E. Giacobini,et al.  From molecular structure to Alzheimer therapy. , 1997, Japanese journal of pharmacology.

[54]  Hiroaki Kazui,et al.  Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? , 2005, The American journal of psychiatry.

[55]  M. Mayhaus,et al.  Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter , 1998, Journal of Physiology-Paris.

[56]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[57]  S. Greenfield,et al.  Bioactivity of a peptide derived from acetylcholinesterase in hippocampal organotypic cultures , 2004, Experimental Brain Research.

[58]  A. Nordberg,et al.  Long‐lasting acetylcholinesterase splice variations in anticholinesterase‐treated Alzheimer's disease patients , 2004, Journal of neurochemistry.

[59]  H. Soreq,et al.  ARP, the cleavable C-terminal peptide of “readthrough” acetylcholinesterase, promotes neuronal development and plasticity , 2007, Journal of Molecular Neuroscience.

[60]  B. Gordon,et al.  Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.

[61]  R. Fukuyama,et al.  The Cerebrospinal Fluid Level of Glial Fibrillary Acidic Protein Is Increased in Cerebrospinal Fluid from Alzheimer’s Disease Patients and Correlates with Severity of Dementia , 2001, European Neurology.

[62]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[63]  P. Walker,et al.  CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation? , 1999, Journal of immunology.

[64]  R. Koeppe,et al.  Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex , 2000, Annals of neurology.

[65]  H. Soreq,et al.  Stress-induced cholinergic signaling promotes inflammation-associated thrombopoiesis. , 2006, Blood.

[66]  Y. Hemo,et al.  The stress-associated acetylcholinesterase variant AChE-R is expressed in human CD34(+) hematopoietic progenitors and its C-terminal peptide ARP promotes their proliferation. , 2002, Experimental hematology.

[67]  Lars Nyberg,et al.  Age-Related Differences in Neural Activity during Item and Temporal-Order Memory Retrieval: A Positron Emission Tomography Study , 2000, Journal of Cognitive Neuroscience.

[68]  Kevin J. Tracey,et al.  Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation , 2002, Nature.

[69]  J. Massoulie,et al.  The readthrough variant of acetylcholinesterase remains very minor after heat shock, organophosphate inhibition and stress, in cell culture and in vivo , 2005, Journal of neurochemistry.

[70]  D. Kaufer,et al.  Anticholinesterases induce multigenic transcriptional feedback response suppressing cholinergic neurotransmission. , 1999, Chemico-biological interactions.

[71]  R. Zahler,et al.  The alpha3 isoform protein of the Na+, K(+)-ATPase is associated with the sites of cardiac and neuromuscular impulse transmission. , 1996, Circulation research.